Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Counting Market

Cell Counting Market Size

  • Report ID: GMI8496
  • Published Date: Mar 2024
  • Report Format: PDF

Cell Counting Market Size

Cell Counting Market size was valued at over USD 11.6 billion in 2023 and is expected to reach over USD 20.6 billion by 2032 due to the increasing incidence of chronic diseases, such as HIV, measles, diphtheria, cancer, and blood disorders. Healthcare providers are actively utilizing cell counting technologies to diagnose and monitor these conditions.

 

The ongoing prevalence of chronic diseases is driving the progression of medical advancements. Additionally, the continuous R&D efforts are making way for more accurate and efficient cell counting techniques, fueling the market expansion. For instance, in November 2023, HIV.gov. published a report stating that approximately 39 million people globally were living with HIV, with 1.3 million new infections in 2022. These figures are emphasizing the importance of precise cell counting and diagnostic tests in combating the spread of HIV.

Of late, academic institutions, research organizations, and industry players are collaborating and partnering to develop innovative cell counting solutions. They are pooling their resources, sharing expertise, and leveraging technologies to advance the field. These collaborations are driving breakthroughs in cell counting techniques and leading to more accurate and efficient methods for researchers.
 

With stakeholders in the market working together to push the boundaries of technology and developing cutting-edge solutions that meet the evolving needs of scientific research, the market will record steady growth. For instance, in May 2024, Galapagos and Adaptimmune initiated a clinical collaboration by potentially integrating cell counting technologies. This partnership aimed to develop innovative solutions, such as uza-cel, for head and neck cancer and other solid tumor indications, further marking a significant stride in advancing cell-based therapies.
 

On the other side, ethical considerations are hindering practices in the cell counting industry and necessitating responsible approaches to technology implementation. Simultaneously, a shortage of skilled personnel trained in operating and interpreting data will remain a constraint. However, the ongoing efforts on enhancing the ethical standards and expanding training programs to meet the future demands in the field may add positive impetus to the market growth.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cell counting market size was valued at over USD 11.6 billion in 2023 and is expected to exceed USD 20.6 by 2032 driven by the rising incidence of chronic diseases such as HIV, measles, diphtheria, cancer, and blood disorders.

The consumables and reagents segment is slated to depict 6.7% CAGR from 2024-2032 as they are essential in facilitating accurate and efficient cell counting processes.

North America cell counting industry size is expected to surpass USD 7.7 billion by 2032 due to the rising investments in healthcare infrastructure and escalating R&D activities.

Prominent cell counting companies include Abbott Laboratories, Agilent Technologies, Inc., Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Biote, Instruments, Inc., ChemoMetec A/S, DeNovix, Merck KGaA, NanoEnTek Inc, Olympus Corporation, Sysmex Corporation, and Thermo Fisher Scientific Inc.

Cell Counting Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 466
  • Countries covered: 19
  • Pages: 180
 Download Free Sample